Preclinical Results for Acetylon Pharmaceuticals’ Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at ASH 2012
18:00 EST 10 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug
discovery and development for enhanced therapeutic outcomes, today
announced results from a preclinical study of a selective histone
deacetylase (HDAC) 1/2 inhi...
Other Sources for this Article
Acetylon Pharmaceuticals Inc.
Walter C. Ogier, 617-245-1300
President
and Chief Executive Officer
wogier@acetylon.com
or
MEDIA:
MacDougall
Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
Michelle
Avery, 781-235-3060
mavery@macbiocom.com
More From BioPortfolio on "Preclinical Results for Acetylon Pharmaceuticals’ Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at ASH 2012"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
